Peter Luo
Known title: Chief Executive OfficerCIK: 0001907614
Peter Luo's purchase track record
Peter Luo has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/16/2026 | ADAG | $64K | pending | pending | — |
| 8/4/2026 | ADAG | $85K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ADAG | ▲ Buy | Open Market | 20,290 | $64K | 9/16/2026 | View on chart |
| ADAG | ▲ Buy | Open Market | 279 | $1K | 8/5/2026 | View on chart |
| ADAG | ▲ Buy | Open Market | 22,966 | $84K | 8/4/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Adagene's ADG138 IND approved by China's NMPA
China's National Medical Products Administration has cleared Adagene's Investigational New Drug application for ADG138, a HER2xCD3 bispecific T-cell engager. This regulatory step allows the company to proceed with clinical development of its proprietary SAFEbody technology in China. The stock is currently trading near its 52-week low, well below the average analyst target price.
Adagene's ADG138 IND approved by China's NMPA. China's National Medical Products Administration has cleared Adagene's Investigational New Drug application for ADG138, a HER2xCD3 bispecific T-cell engager. This regulatory step allows the company to proceed with clinical development of its proprietary SAFEbody technology in China. The stock is currently trading near its 52-week low, well below the average analyst target price.